EUVIMEDEUVIMED entdecken
Crossref

Treatment of Meticillin‐Resistant Staphylococcus Pyoderma With Rifampicin in 104 Dogs: Clinical Outcomes, Adverse Effects, and Rifampicin Resistance in Nonresponders

Tian Chee Lu iD, David Robson, Greg Burton

Veterinary Dermatology · 2025

DOI: 10.1111/vde.70032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary Dermatology, 2025. Verfasst von Tian Chee Lu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Animal Skin and Ear Specialists, Melbourne Veterinary Specialist Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Rifampin, Dog Diseases, Pyoderma, Anti-Bacterial Agents. Die Arbeit nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Meticillin‐resistant Staphylococcus pseudintermedius (MRSP) is often resistant to multiple antibiotics. Rifampicin is effective against most MRSP isolates, yet the potential for the development of rapid resistance raises questions regarding its suitability as an antibiotic monotherapy for MRSP pyoderma.

Objectives

To describe the: (i) clinical outcome of rifampicin antibiotic monotherapy in MRSP pyoderma; (ii) frequency of adverse effects; and (iii) development of rifampicin resistance among dogs considered nonresponders to therapy. Materials and Methods A retrospective study of medical records from 1/1/2013 to 1/12/2022 of client‐owned dogs with MRSP pyoderma treated with oral rifampicin as a systemic antibiotic monotherapy for 21 days.

Results

104 dogs were included; 77 cases of superficial pyoderma (74%) and 27 cases of deep pyoderma (26%). The mean daily rifampicin dose was 6 mg/kg. Rifampicin was clinically effective in 86 cases (82.7%). Eleven of 18 nonresponding dogs demonstrated rapidly acquired rifampicin resistance (10.6%). Eighty‐two (78.8%), 17 (16.3%), two (1.9%) and three (2.9%) dogs experienced zero, mild, moderate and severe adverse effects, respectively. Conclusions and Clinical Relevance Rifampicin at 6 mg/kg is an effective and mostly well‐tolerated monotherapy for treating MRSP pyoderma. However, in this study, it was associated with rapid development of resistance in ≥ 10% of treated dogs. Inadequate clinical response occurred without demonstrable resistance in 6.7% of cases. Concurrent use of ciclosporin or fluconazole with rifampicin increased the odds of severe adverse reactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinDog DiseasesPyodermaAnti-Bacterial AgentsStaphylococcusStaphylococcal Skin InfectionsAnimalsDogsRetrospective StudiesFemaleMaleTreatment OutcomeMethicillin ResistanceDrug Resistance, Bacterial

Stichwörter der Autor:innen

MRSPdogspyodermarifampicinrifampicin‐resistance

Substanzen

RifampinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Animal Skin and Ear Specialists, Melbourne Veterinary Specialist Centre, Melbourne, Victoria, Australia.

ORCID-Profile: Tian Chee Lu

Zitieren

APA

Lu, T. C., Robson, D., & Burton, G. (2025). Treatment of Meticillin‐Resistant Staphylococcus Pyoderma With Rifampicin in 104 Dogs: Clinical Outcomes, Adverse Effects, and Rifampicin Resistance in Nonresponders. Veterinary Dermatology. https://doi.org/10.1111/vde.70032

Vancouver

Lu TC, Robson D, Burton G. Treatment of Meticillin‐Resistant Staphylococcus Pyoderma With Rifampicin in 104 Dogs: Clinical Outcomes, Adverse Effects, and Rifampicin Resistance in Nonresponders. Veterinary Dermatology. 2025. doi:10.1111/vde.70032

BibTeX
@article{Lu2025,
  author = {Lu, Tian Chee and Robson, David and Burton, Greg},
  title = {Treatment of Meticillin‐Resistant Staphylococcus Pyoderma With Rifampicin in 104 Dogs: Clinical Outcomes, Adverse Effects, and Rifampicin Resistance in Nonresponders},
  journal = {Veterinary Dermatology},
  year = {2025},
  doi = {10.1111/vde.70032}
}
Kostenlos starten →